Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan Builds Asia Links Through New AMED Programs

Executive Summary

In line with similar initiatives by Japan on other regulatory fronts, the country's Agency for Medical Research and Development is building up its partnerships and presence in Asia.

You may also be interested in...



ICH Consults On Supporting Multi-Regional Trials, Non-Clinical Evaluation Of Anticancer Drugs

The International Council on Harmonisation has endorsed draft versions of two new guidelines – one on conducting multi-regional clinical trials and the other on supporting the non-clinical evaluation of anticancer medicines. The ICH is now seeking stakeholder feedback on both documents.

G7 Health Topics: Plenty Of Talk, Limited Action

Pushed in part by host Japan, health issues including antimicrobial resistance and incentives for drug R&D in this and other sectors formed an important part of the agenda at last week's G7 meeting. But while there was plenty of recognition of important issues, concrete progress was limited.

Progress For Asian Associations As Regulatory Roadmap Recognized

An industry-led grouping of research-based pharma associations from across Asia has held its latest annual meeting in Tokyo at which it reported modest but steady progress across initiatives in the regulatory and drug discovery areas as it seeks to get novel medicines to patients faster.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM006764

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel